Studying Chromosomes in Samples From Younger Patients With Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research studies chromosomes in samples from younger patients with neuroblastoma.
Genetic: DNA analysis
Genetic: nucleic acid amplification
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis
|Official Title:||Prognostic Impact of Segmental Chromosome Aberrations in Non MYCN Amplified Neuroblastomas in Different Age Groups|
- Overall survival (OS) calculated from the date of diagnosis to the date of death from any cause estimated by the Kaplan-Meier method [ Designated as safety issue: No ]
- Event-free survival (EFS) calculated from the date of diagnosis to the date of disease progression, death from any cause, or secondary neoplasm estimated by the Kaplan-Meier method [ Designated as safety issue: No ]
- Incidence of metastatic relapses using cumulative incidences [ Designated as safety issue: No ]
- Difference in patients with and without segmental aberrations using the log rank-test and Grey's test and the model of Fine and Grey for the evaluation of statistical significance [ Designated as safety issue: No ]
- Interactions between age and segmental aberrations using Cox' regression model [ Designated as safety issue: No ]
|Study Start Date:||April 2012|
|Estimated Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
- Determine the impact on overall survival of patients with non-MYCN neuroblastoma below 18 months of age as compared to neuroblastoma patients above 18 months of age.
OUTLINE: Archived DNA samples are analyzed for segmental chromosome aberrations by multiplex ligation-dependent probe amplification (MLPA), a polymerase chain reaction (PCR)-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
|Principal Investigator:||Peter F. Ambros, PhD||Children's Cancer Research Institute|